These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34082305)

  • 1. Systematic assessment of structure-promiscuity relationships between different types of kinase inhibitors.
    Hu H; Bajorath J
    Bioorg Med Chem; 2021 Jul; 41():116226. PubMed ID: 34082305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic computational identification of promiscuity cliff pathways formed by inhibitors of the human kinome.
    Miljković F; Vogt M; Bajorath J
    J Comput Aided Mol Des; 2019 Jun; 33(6):559-572. PubMed ID: 30915709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Data structures for computational compound promiscuity analysis and exemplary applications to inhibitors of the human kinome.
    Miljković F; Bajorath J
    J Comput Aided Mol Des; 2020 Jan; 34(1):1-10. PubMed ID: 31792884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping Biological Activities to Different Types of Molecular Scaffolds: Exemplary Application to Protein Kinase Inhibitors.
    Dimova D; Bajorath J
    Methods Mol Biol; 2018; 1825():327-337. PubMed ID: 30334211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promiscuity analysis of a kinase panel screen with designated p38 alpha inhibitors.
    González-Medina M; Miljković F; Haase GS; Drueckes P; Trappe J; Laufer S; Bajorath J
    Eur J Med Chem; 2020 Feb; 187():112004. PubMed ID: 31881458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
    Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
    J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure- and Similarity-Based Survey of Allosteric Kinase Inhibitors, Activators, and Closely Related Compounds.
    Laufkötter O; Hu H; Miljković F; Bajorath J
    J Med Chem; 2022 Jan; 65(2):922-934. PubMed ID: 33476146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity profile relationships between structurally similar promiscuous compounds.
    Hu Y; Bajorath J
    Eur J Med Chem; 2013 Nov; 69():393-8. PubMed ID: 24077530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying representative kinases for inhibitor evaluation via systematic analysis of compound-based target relationships.
    Laufkötter O; Laufer S; Bajorath J
    Eur J Med Chem; 2020 Oct; 204():112641. PubMed ID: 32745818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping of inhibitors and activity data to the human kinome and exploring promiscuity from a ligand and target perspective.
    Hu Y; Kunimoto R; Bajorath J
    Chem Biol Drug Des; 2017 Jun; 89(6):834-845. PubMed ID: 27933727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
    Gao Y; Davies SP; Augustin M; Woodward A; Patel UA; Kovelman R; Harvey KJ
    Biochem J; 2013 Apr; 451(2):313-28. PubMed ID: 23398362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the scaffold universe of kinase inhibitors.
    Hu Y; Bajorath J
    J Med Chem; 2015 Jan; 58(1):315-32. PubMed ID: 25192260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unprecedently Large-Scale Kinase Inhibitor Set Enabling the Accurate Prediction of Compound-Kinase Activities: A Way toward Selective Promiscuity by Design?
    Christmann-Franck S; van Westen GJ; Papadatos G; Beltran Escudie F; Roberts A; Overington JP; Domine D
    J Chem Inf Model; 2016 Sep; 56(9):1654-75. PubMed ID: 27482722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring structure-promiscuity relationships using dual-site promiscuity cliffs and corresponding single-site analogs.
    Hu H; Bajorath J
    Bioorg Med Chem; 2020 Jan; 28(1):115238. PubMed ID: 31818631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approach in Improving Potency and Selectivity of Kinase Inhibitors: Allosteric Kinase Inhibitors.
    Wei S; Zhao T; Wang J; Zhai X
    Mini Rev Med Chem; 2021; 21(8):991-1003. PubMed ID: 33355051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leveraging Structural Diversity and Allosteric Regulatory Mechanisms of Protein Kinases in the Discovery of Small Molecule Inhibitors.
    Verkhivker GM
    Curr Med Chem; 2017; 24(42):4838-4872. PubMed ID: 27719654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.
    Kwarcinski FE; Brandvold KR; Phadke S; Beleh OM; Johnson TK; Meagher JL; Seeliger MA; Stuckey JA; Soellner MB
    ACS Chem Biol; 2016 May; 11(5):1296-304. PubMed ID: 26895387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Makes a Kinase Promiscuous for Inhibitors?
    Hanson SM; Georghiou G; Thakur MK; Miller WT; Rest JS; Chodera JD; Seeliger MA
    Cell Chem Biol; 2019 Mar; 26(3):390-399.e5. PubMed ID: 30612951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redefining the Protein Kinase Conformational Space with Machine Learning.
    Ung PM; Rahman R; Schlessinger A
    Cell Chem Biol; 2018 Jul; 25(7):916-924.e2. PubMed ID: 29861272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing Scaffold Diversity of Kinase Inhibitors Using Alternative Scaffold Concepts and Estimating the Scaffold Hopping Potential for Different Kinases.
    Dimova D; Bajorath J
    Molecules; 2017 May; 22(5):. PubMed ID: 28467353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.